ACAD
27.08
-1.17
-4.14%
AEMD
4.8
+0.15
+3.23%
APRI
1.24
-0.05
-3.88%
ARNA
1.4
-0.08
-5.41%
ATEC
4.85
-0.07
-1.42%
CNAT
1.96
+0.04
+2.08%
CRXM
0.17
+0.00
+0.0589%
CYTX
1.55
0.00
0.00%
DXCM
63.04
-2.44
-3.73%
GNMK
10.98
-0.26
-2.31%
HALO
11.31
-0.57
-4.80%
ILMN
122.02
-4.38
-3.47%
INNV
0.263
+0.003
+1.0769%
INO
6.97
-0.34
-4.65%
ISCO
1.31
+0.11
+9.17%
ISIS
0
0.00
0.00%
LGND
102.59
-3.28
-3.10%
LPTN
2.62
-0.06
-2.2351%
MBVX
4.06
+0.03
+0.74%
MEIP
1.54
-0.03
-1.91%
MNOV
7.58
-0.03
-0.39%
MRTX
5.35
+0.25
+4.90%
MSTX
0.083
+0.001
+1.7073%
NBIX
42.94
-2.09
-4.64%
NUVA
66.83
+0.2
+0.30%
ONCS
1.348
-0.002
-0.1778%
ONVO
3.09
-0.07
-2.22%
OREX
1.84
-0.1
-5.15%
OTIC
16.2
0.00
0.00%
QDEL
22.2
-0.03
-0.13%
RCPT
0
0.00
0.00%
RGLS
2.65
0.00
0.00%
RMD
60.34
+0.56
+0.94%
SCIE
0.002
0.00
-5.2632%
SPHS
2.74
-0.03
-1.08%
SRNE
5.2
-0.2
-3.70%
TROV
2.3
-0.2
-8.00%
VICL
2.34
+0.02
+0.86%
ZGNX
13
-0.25
-1.89%
ACAD
27.08
-1.17
-4.14%
AEMD
4.8
+0.15
+3.23%
APRI
1.24
-0.05
-3.88%
ARNA
1.4
-0.08
-5.41%
ATEC
4.85
-0.07
-1.42%
CNAT
1.96
+0.04
+2.08%
CRXM
0.17
+0.00
+0.0589%
CYTX
1.55
0.00
0.00%
DXCM
63.04
-2.44
-3.73%
GNMK
10.98
-0.26
-2.31%
HALO
11.31
-0.57
-4.80%
ILMN
122.02
-4.38
-3.47%
INNV
0.263
+0.003
+1.0769%
INO
6.97
-0.34
-4.65%
ISCO
1.31
+0.11
+9.17%
ISIS
0
0.00
0.00%
LGND
102.59
-3.28
-3.10%
LPTN
2.62
-0.06
-2.2351%
MBVX
4.06
+0.03
+0.74%
MEIP
1.54
-0.03
-1.91%
MNOV
7.58
-0.03
-0.39%
MRTX
5.35
+0.25
+4.90%
MSTX
0.083
+0.001
+1.7073%
NBIX
42.94
-2.09
-4.64%
NUVA
66.83
+0.2
+0.30%
ONCS
1.348
-0.002
-0.1778%
ONVO
3.09
-0.07
-2.22%
OREX
1.84
-0.1
-5.15%
OTIC
16.2
0.00
0.00%
QDEL
22.2
-0.03
-0.13%
RCPT
0
0.00
0.00%
RGLS
2.65
0.00
0.00%
RMD
60.34
+0.56
+0.94%
SCIE
0.002
0.00
-5.2632%
SPHS
2.74
-0.03
-1.08%
SRNE
5.2
-0.2
-3.70%
TROV
2.3
-0.2
-8.00%
VICL
2.34
+0.02
+0.86%
ZGNX
13
-0.25
-1.89%
Home » Hugo Villar, Ph.D., MBA-Bio

Hugo Villar, Ph.D., MBA-Bio

Hugo O. Villar Ph.D., MBA is director for Science and Technology programs at UC San Diego Extension. He is also President of Altoris, Inc. a San Diego based specializing in information management for the biotech and pharmaceutical industries and providing consulting on discovery technologies. He was Vice President for Chemoproteomics at Triad Therapeutics and Vice President of Discovery Technologies at Telik, Inc. His work resulted in over 80 publications and 18 patents on the development of technologies for drug discovery. He has a Ph.D. in Chemistry and an MBA with a concentration in Pharmaceuticals and Helathcare.